Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (1723)	5/3/1999 11:05:00 PM
From: Greg Spendjian	Respond to of 14101

Thanks very much for this press release Bluejay. I had not seen it before. I wonder if DMX never released this bit of news. If there are positive results with this Phase III study, we are going to have a lot of people sit up and take note. Though the patients receive WF10 for 11 weeks the follow up is for two years, so it is difficult to tell when the first results will be reported. It surprises me that they have got going with a partial group (60 out of 240) instead of waiting to have everyone enrolled. Let us hope for the best, especially for the patients themselves. Greg

To: DaveAu who wrote (1723)	5/4/1999 7:12:00 AM
From: Tom Drolet	Respond to of 14101

Bluejay: Great find. Thanks. The streaming video of Dr. McGrath is worth a listen/watch-- on the first page--requires Realplayer. Greg--right on-- lets get on with it--patients are dying.

To: DaveAu who wrote (1723)	5/4/1999 8:51:00 AM
From: Montana Wildhack	Respond to of 14101

Results from an earlier well-controlled clinical trial at Vanderbilt University in Nashville, TN were published in the journal Infection (August 1998). The study indicated that AIDS patients receiving WF10 experienced a lower frequency of opportunistic infections, fewer hospitalizations, and longer survival. As I recall the results were dramatic. None of the patients receiving placebo survived, while most getting WF10 did survive and more compelling - the patients getting WF10 needed virtually no hospital days while the placebo group needed many.